Mediwound announces positive results in its u.s. phase i/ii study of mw005 for the treatment of basal cell carcinoma

Mw005 shown to be safe and well-tolerated data provide clinical efficacy proof-of-concept based on clearance of target lesions yavne, israel, july 10, 2023 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its phase i/ii study to evaluate the safety and efficacy of mw005 in the treatment of low-risk basal cell carcinoma (bcc).
MDWD Ratings Summary
MDWD Quant Ranking